Gilead licenses three Vir masked T-cell engagers in deal worth up to $1.9bn

Gilead Sciences has agreed to license three T-cell engagers to be built on Vir Biotechnology's dual-masked PRO-XTEN platform, in an agreement disclosed on 14 October 2026 with a potential value of $1.9 billion ¹. It is the second big pharma licence for the platform this year, after Astellas signed a deal in February that could be worth $1.7 billion ¹.

The terms

Vir receives $90 million upfront, made up of $65 million in cash and a $25 million equity investment priced at a 30% premium ¹. A further $45 million is tied to near-term preclinical milestones, followed by up to $1.74 billion in development, regulatory and commercial milestones, plus tiered royalties from high single digits to low double digits on sales ¹.

The division of work is clear. Vir discovers, designs and optimises three candidates aimed at antigens associated with solid tumours. Gilead has exclusive rights to nominate candidates and then takes on development, manufacturing and commercialisation ¹. The targets have already been chosen, according to Vir chief executive Marianne De Backer, who did not describe the intended indications ¹. "These are three targets that we were not interested in exploring ourselves," she said, adding that the arrangement lets Vir concentrate on its own programmes while bringing in non-dilutive money ¹.

Where AI fits

The technology addresses the main obstacle for T-cell engagers in solid tumours, which is toxicity. PRO-XTEN places masks over both the tumour-binding and the T-cell-binding domains, so the molecule stays inactive until proteases specific to the tumour remove them ¹. De Backer described the platform as modular, because the same mask can be reused across optimised molecules rather than designed afresh each time ¹. Vir also uses an in-house AI system, dAIsy, to optimise its engagers: "We are extremely efficient in coming up with powerful T-cell engagers, then using our AI engine dAIsy to optimize them," she said ¹.

What it means for the market

For Gilead, the deal adds early-stage oncology options at modest upfront cost after a year of much larger spending. Earlier in 2026 it bought Arcellx for $7.8 billion and paid $3.15 billion upfront for the ADC developer Tubulis, while its lead solid tumour drug Trodelvy has run into several clinical setbacks, most recently in first-line non-small cell lung cancer ¹. Chief executive Dan O'Day has said the company's push into oncology and immunology is now large enough and that future M&A would build on it ¹.

For Vir, two platform licences in eight months turn the masking technology into a source of income that funds its own pipeline. Astellas paid $315 million upfront in February, in cash and equity, for the PSMA-targeting VIR-5500, which has early clinical data and FDA fast track designation in prostate cancer; the partners plan to move it into Phase 3 next year ¹. De Backer said Vir has more opportunities on the platform than it can pursue alone and sees "an opportunity to do more deals in the masked T-cell engager space" ¹. For investors in protein engineering platforms, the pattern is a modest upfront with most of the value deferred into milestones, and a buyer that leaves target selection to the deal rather than to the platform owner.

Caveats

Almost all of the $1.9 billion headline depends on milestones that may never be paid, and the programmes are at the discovery stage, with no candidate yet named ¹. The deal comes as Vir nears registrational data for its hepatitis delta combination of elebsiran and tobevibart, a potential rival to Gilead's Hepcludex ¹. Vir also expects Phase 1 dose escalation data for its HER2 engager VIR-5818 later this year ¹.